Estimation of Drug Pharmacokinetics from Breast Feeding: A Simple Method Based on Meta-analysis

Main Article Content

Oumar Aboubacar Alassane
De Pablos-Martinez Carlos
Maiga Mamoudou
Dao Sounkalo
Chatelut Etienne
Gandia Peggy

Abstract

Background: In resource-limited settings, breastfeeding is the healthiest source of nutrition for newborns. For economic/cultural reasons, breastfeeding is the preferred option for the majority of mothers, including HIV-positive mothers.

Objective: The objective of this review is to document parameters characterizing antiretroviral therapy (ARV) diffusion into breast milk associated with the estimated ARV amount ingested by breastfed infant and clinical/biological abnormalities.

Data Source and Eligibility Criteria: Twenty seven (27) published articles on the aspects of Pharmacokinetic parameters on ARV diffusion into breast milk have shown a large variability without clear interpretation on drugs diffusion. Using PubMed and Embase, we conducted a search to identify all published studies at 2015 that characterized antiretroviral drug diffusion from mother to infant via breast milk. We identified 27 published studies that characterized antiretroviral drug passage from mother to infant (drug concentrations in mother’s milk and breastfed plasma). Information was sufficiently complete for inclusion in the present analysis for only six antiretroviral drugs.

Results: Finally, only data for nevirapine and efavirenz were exploitable because some of the studies found null or non-detectable levels, which were not suitable for simulations. Median (IQR) nevirapine CL/F were 0.022 (0.013-0.038) for newborns, 0.121 (0.116-0.125) for children and 0.056 (0.045-0.070) for mothers, all in L/h/kg. Efavirenz CL/F were 0.025 (0.016-0.039) for newborns, 0.273 (0.261-0.285) for children and 0.160 (0.153-0.167) for mothers, also in L/h/kg.

Conclusion: Pharmacokinetics parameters of efavirenz and nevirapine are important to be determined in breastfed newborns.

Keywords:
Breast milk, antiretroviral drugs, newborn exposure.

Article Details

How to Cite
Alassane, O., Carlos, D. P.-M., Mamoudou, M., Sounkalo, D., Etienne, C., & Peggy, G. (2019). Estimation of Drug Pharmacokinetics from Breast Feeding: A Simple Method Based on Meta-analysis. Journal of Advances in Medical and Pharmaceutical Sciences, 21(2), 1-8. https://doi.org/10.9734/jamps/2019/v21i230126
Section
Review Article

References

Breastfeeding and the use of human milk. American Academy of Pediatrics. Work Group on Breastfeeding. Pediatrics. 1997; 100(6):1035-9.

Eidelman AI. Breastfeeding and the use of human milk: An analysis of the American Academy of Pediatrics 2012 Breastfeeding Policy Statement. Breastfeed Med. 2012; 7(5):323-4.

Ip S, Chung M, Raman G, Trikalinos TA, Lau J. A summary of the agency for healthcare research and quality's evidence report on breastfeeding in developed countries. Breastfeed Med. 2009;4(Suppl 1):S17-30.

Horta BL, Victoria CG. Long-term effects of breastfeeding: A systematic review. In: Organization WH, ed. GENEVA: WHO; 2013.

Eidelman AI, Schanler RJ. American academy of pediatrics section on breastfeeding. Breastfeeding and the Use of Human Milk. Pediatrics. 2012;129(3): e827-e41.

Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet. 2013;382(9890):427-51.

Lamberti LM, Fischer Walker CL, Noiman A, Victora C, Black RE. Breastfeeding and the risk for diarrhea morbidity and mortality. BMC Public Health. 2011; 11(Suppl 3):S15.

Lamberti LM, Zakarija-Grkovic I, Fischer Walker CL, Theodoratou E, Nair H, Campbell H, et al. Breastfeeding for reducing the risk of pneumonia morbidity and mortality in children under two: a systematic literature review and meta-analysis. BMC Public Health. 2013;13 (Suppl 3):S18.

WHO/UNICEF. Global strategy on infant and young child feeding. In: WHO, ed. GENEVA: WHO; 2003.

WHO/, UNAIDS/, UNFPA/, UNICEF. Guidelines on HIV and infant feeding. Principles and recommendations for infant feeding in the context of HIV and a summary of evidence. . GENEVA: WHO; 2010.

WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommenda-tions for a public health approach. GENEVA: WHO. 2013;272.

Zeh C, Weidle PJ, Nafisa L, Lwamba HM, Okonji J, Anyango E, et al. HIV-1 drug resistance emergence among breast-feeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8(3):e1000430.

Palombi L, Pirillo MF, Andreotti M, Liotta G, Erba F, Sagno JB, et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: Drug concentrations, virological efficacy and safety. Antiviral Therapy. 2012;17(8):1511-9.

Fogel J, Li Q, Taha TE, Hoover DR, Kumwenda NI, Mofenson LM, et al. Initiation of antiretroviral treatment in women after delivery can induce multiclass drug resistance in breastfeeding HIV-infected infants. Clin Infect Dis. 2011;52(8): 1069-76.

Dryden-Peterson S, Shapiro RL, Hughes MD, Powis K, Ogwu A, Moffat C, et al. Increased risk of severe infant anemia after exposure to maternal HAART, Botswana. J Acquir Immune Defic Syndr. 2011;56(5):428-36.

WHO. March 2014 Supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommenda-tions for a public health approach. . GENEVA: WHO; 2014.

Bonate PL. A brief introduction to monte carlo simulation. Clin Pharmacokinet. 2001;40(1):15-22.

Raychaudhuri S. Introduction to Monte Carlos Simulation. Winter Simulation Conference. Austin, TX: IEEE. 2008:91- 100.

Salem AH, Fletcher CV, Brundage RC. Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children. Antimicrobial Agents and Chemotherapy. 2014;58(1):136-43.

Cooper CL, van Heeswijk RP. Once-daily nevirapine dosing: A pharmacokinetics, efficacy and safety review. HIV Medicine. 2007;8(1):1-7.

Benaboud S, Treluyer JM, Urien S, Blanche S, Bouazza N, Chappuy H, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrobial Agents and Chemotherapy. 2012;56(2):776-82.

Piana C, Zhao W, Adkison K, Burger D, Jacqz-Aigrain E, Danhof M, et al. Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children. British Journal of Clinical Pharmacology. 2014;77(5):861-72.

Vreeman RC, Nyandiko WM, Liechty EA, Busakhala N, Bartelink IH, Savic RM, et al. Impact of adherence and anthropometric characteristics on nevirapine pharma-cokinetics and exposure among HIV-infected Kenyan children. J Acquir Immune Defic Syndr. 2014;67(3):277-86.

Fogel JM, Taha TE, Sun J, Hoover DR, Parsons TL, Kumwenda JJ, et al. Stavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants. J Acquir Immune Defic Syndr. 2012;60(5): 462-5.

Schneider S, Peltier A, Gras A, Arendt V, Karasi-Omes C, Mujawamariwa A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr. 2008;48(4):450-4.

Fletcher CV, Brundage RC, Fenton T, Alvero CG, Powell C, Mofenson LM, et al. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. Clin Pharmacol Ther. 2008;83(2):300-6.

Hoody DW, Fletcher CV. Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children. Semin Pediatr Infect Dis. 2003;14(4):286-94.

Pearce RE, Gaedigk R, Twist GP, Dai H, Riffel AK, Leeder JS, et al. Developmental Expression of CYP2B6: A comprehensive analysis of mrna expression, protein content and bupropion hydroxylase activity and the impact of genetic variation. Drug Metab Dispos; 2015.

Nikanjam M, Kabamba D, Cressey TR, Burger D, Aweeka FT, Acosta EP, et al. Nevirapine exposure with WHO pediatric weight band dosing: Enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. Antimicrobial Agents and Chemotherapy. 2012;56(10):5374-80.

Dickinson L, Chaponda M, Carr DF, van Oosterhout JJ, Kumwenda J, Lalloo DG, et al. Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. Antimicrobial agents and chemotherapy. 2014;58(2):706-12.

Brown KC, Hosseinipour MC, Hoskins JM, Thirumaran RK, Tien HC, Weigel R, et al. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. Pharmacogenomics. 2012;13(1):113-21.

de Wildt SN. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opinion on Drug Metabolism & Toxicology. 2011;7(8):935-48.

Musoke P, Guay LA, Bagenda D, Mirochnick M, Nakabiito C, Fleming T, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999; 13(4):479-86.